Castration experiments in rodents show that the stromal vasculature is critical to the androgen-mediated prostate growth regulation. However, the role of angiogenesis inhibitors, such as thrombospondin-1 (TSP-1), in this process is unclear. TSP-1 is a multifunctional glycoprotein that can function as a potent angiogenesis inhibitor and an in vivo activator of latent transforming growth factor-b (TGF-b) in some tissues. On the basis of these observations, we hypothesized that TSP-1 regulated androgen withdrawal-induced prostate regression and that this process was mediated not only through antiangiogenic activity but also through TGF-b activation. To test this, we evaluated angiogenic activity in human prostate epithelial and stromal cells treated with androgens and hypoxia in vitro. TSP-1 knockout mice were characterized to investigate the in vivo functions of TSP-1. In vitro, we found that androgens and hypoxia differentially regulated TSP-1 and angiogenic activity. Androgens stimulated normal epithelial cell, but inhibited normal stromal cell, angiogenic activity. Conversely, hypoxia stimulated stromal while inhibiting epithelial activity. Thus, in vivo, net angiogenic activity must reflect cellular interactions. And, we found that media conditioned by epithelial cells grown under normoxic conditions stimulated stromal cell angiogenic activity, and if epithelial cells were grown under hypoxic conditions, stromal activity was further increased. TSP-1 levels, however, were unchanged. In vivo, TSP-1 loss in a mouse model led to prostate epithelial hyperplasia by 3 months of age with only a modest stromal effect. Androgens suppressed TSP-1 as expression increased after castration both in normal mouse prostate and in human prostate cancer tissues. In addition, TSP-1 expression corresponded to increased TGF-b activation in mouse tissues, specifically in the stromal compartment. These data show a critical role for TSP-1 in prostate epithelial and stromal growth regulation through angiogenic inhibition and activation of latent TGF-b. Therefore, loss of TSP-1 during tumorigenesis would eliminate two barriers to cancer progression.
Androgens stimulate prostate growth during development, and maintain the gland in adulthood. This modulation of prostate growth by androgens is mediated in part through regulation of angiogenesis. In the normal adult prostate, blood vessels are maintained in a quiescent state in the stroma by a predominance of angiogenic inhibitors over inducers in the tissue milieu. Induction of angiogenesis is necessary for tumor progression, and supporting this, many studies have shown that increased microvascular density (MVD) has prognostic value in prostate cancer (PCa) patients. [1] [2] [3] [4] We have previously shown that, compared to normal prostate epithelial cells (PrECs), the balance of angiogenic mediators is altered in PCa cells; 5, 6 however, the stromal contribution to angiogenesis has not been well studied.
In the normal rodent prostate, androgen withdrawal induces endothelial cell apoptosis and vascular regression before epithelial cell apoptosis. [7] [8] [9] [10] [11] [12] [13] The initial vascular regression is likely due to a sharp decrease in levels of the angiogenesis inducer, vascular endothelial growth factor (VEGF). 14 In the rat prostate, the microvascular endothelial cells do not express the androgen receptor. 15, 16 Thus, rather than a direct effect on the endothelial cells, the effects of androgen withdrawal are likely mediated through the androgen receptor-positive epithelial and stromal cells. Supporting this, androgen treatment does stimulate VEGF expression in normal PrECs and in androgen-sensitive PCa cells. 12, 17 However, in the rat model, VEGF levels rebound to baseline by 3 days after castration. [18] [19] [20] This rebound is likely due to the tissue hypoxia resulting from the vascular regression. [18] [19] [20] However, despite the hypoxia-induced increase in VEGF, vascular regression continues. These observations indicate that other angiogenic mediators must participate in suppressing the vasculature. We have previously shown increased expression of the angiogenesis inhibitor, pigment epithelium-derived factor (PEDF), after androgen withdrawal in both rodent and human PCa tissues, 6 thus, identifying one inhibitor in the continued regression. We have also observed that another angiogenesis inhibitor, thrombospondin-1 (TSP-1), is strongly expressed in normal prostate tissues, and this expression is downregulated in human PCa tissues. 5 In vitro, the TSP-1 secreted by normal PrECs functions as an angiogenesis inhibitor. 5 Colombel et al 21 have observed increased TSP-1 expression after castration in a rat model, and in PCa patients receiving androgen deprivation therapy (ADT), tissue levels of TSP-1 increased whereas VEGF decreased compared to those patients who had no hormone therapy. 4 These observations suggest that TSP-1 could be a second angiogenesis inhibitor functioning in the continued vascular regression. However, the direct effect of androgens and hypoxia on TSP-1 regulation and angiogenic activity in normal prostate epithelial and stromal cells has not been investigated.
TSP-1 is a multifunctional glycoprotein secreted by a variety of cell types, including endothelial and epithelial cells, fibroblasts and smooth muscle cells, 22 so its inhibitory effects on the prostate are unlikely to be through angiogenic regulation alone. TSP-1 activates latent transforming growth factor-b (TGF-b) in vivo in some tissues, [23] [24] [25] and TGF-b inhibits proliferation and stimulates apoptosis of normal prostatic epithelial cells and functions in stromal differentiation. In the early stages of PCa, TGF-b inhibits tumor progression. 26 Therefore, TSP-1 activation of TGF-b could be critical in regulating prostate growth. Similar to TSP-1, TGF-b levels increase in the human prostate after castration, 27 suggesting that TGF-b may function in the regression process. Interestingly, in normal rat prostatic epithelial cells, either 1a,25-dihydroxy vitamin D3 or retinoic acid increased both TSP-1 and TGF-b expression, and the increase in TSP-1 could be inhibited by anti-TGF-b antibodies. 28 These data suggest coordinated regulation between these molecules in the prostate.
On the basis of the above observations, we hypothesized that the angiogenesis inhibitor TSP-1 has a major role in prostate growth and homeostasis and has a critical role in the androgen withdrawal response. Moreover, function of TSP-1 in both epithelial and stromal cells was mediated not only through its antiangiogenic activity but also, in part, through its activation of latent TGF-b. To test this hypothesis, we evaluated the in vitro angiogenic activity of normal PrECs and cancer epithelial cells as well as normal stromal cells to the two stimuli important in the castration responseandrogen and hypoxia. To evaluate the function of TSP-1 in the prostate in vivo, we used a surgical castration model and characterized the prostate phenotype of TSP-1 knockout (KO) mice.
MATERIALS AND METHODS Cell Culture
Human normal prostate epithelial and stromal cell strains and dermal microvascular endothelial cells were purchased from Lonza (Walkersville, MD, USA) and maintained per the manufacturer's instructions. PCa cell lines DU145, LNCaP and PC-3 were obtained from the American Type Culture Collection and maintained in Dulbecco's modified Eagle's medium plus 10% fetal bovine serum and antibiotics. Short-term cultures of normal prostate stromal cells (PrSCs) were established as described. 5, 6 Androgen treatments were performed using the testosterone derivative, dihydrotestosterone (DHT) at 0-10 À7 M as previously described. 6 For hypoxia experiments, normoxia was standard culture conditions (20% O 2 ), and hypoxia was induced by growth at 0.5% O 2 in a hypoxia chamber or by treatment with 100 mM cobalt chloride (CoCl 2 ), a chemical mimic of hypoxia.
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TGF-b neutralizing antibody (Genzyme) was used at 10 mg/ml. Serum-free conditioned media was collected as described. 5, 6 Results were analyzed from at least two independent experiments on each cell type with consistent results.
Angiogenesis Assay
Angiogenic activity in the conditioned media was evaluated using the microvascular endothelial cell migration assay as previously described. 5 Serum-free medium, containing 0.1% bovine serum albumin, served as the control for background migration, and human VEGF (250-500 pg/ml) or basic fibroblast growth factor (15 ng/ml) (R&D Systems, Minneapolis, MN, USA) served as the positive control (250-500 pg/ml). Neutralizing TSP-1 antibody (clone A4.1; Thermo Fisher, Fremont, CA, USA) was used at 40 mg/ml as previously described. 5 Controls for the neutralizing activity of this antibody were included in the assays (Supplementary Figure 1a) , and we have previously shown the specificity of this antibody to TSP-1.
30,31 CoCl 2 (0-100 mM) and DHT (0-10 À7 M) were also tested alone as controls, and no change in activity from background levels was observed with either substance (Supplementary Figure 1b,c ). All samples were tested in quadruplicate, and results were reported as mean percent of maximal migration toward the positive control ± standard error (s.e.).
Protein Analysis TSP-1 and PEDF levels in serum-free conditioned media were analyzed by western blot as previously described. 
Animal Model
The construction of the TSP-1 KO mouse has been described. 32 Prostate tissues from TSP-1 KO and wild-type C57Bl/6 control mice, the background strain of the TSP-1 KO model, were harvested from mice at 1-25 months of age at seven time points (1, 3, 6, 9, 12, 18 and 25 months). At least five mice per age group were used for comparison between genotypes. Castration was performed on wild-type and TSP-1 KO mice at 5-6 months of age, and prostate tissues were harvested at days 1-21 after castration (time points 1, 3, 5, 7, 14 and 21 days; n ¼ 5 per group). All animals used in these studies were housed in accordance with guidelines from the American Association for Laboratory Animal Care, and all research protocols were approved by the Institutional Animal Care and Use Committee.
Human Prostate Tissues
Human prostate biopsy specimens were taken before and 3-7 days after surgical castration from PCa patients (n ¼ 8) at Umea University (Umea, Sweden). Human tissue collection was approved by internal review board committees and all guidelines for patient consent were followed.
Tissue Analysis
Tissues were formalin-fixed, paraffin-embedded and sectioned for staining. A hematoxylin and eosin (H&E) stain was performed for tissue characterization, and an avidin/ biotin/peroxidase protocol was used for immunostaining. Antibodies were used as followed: anti-TSP-1 (Thermo Fisher), anti-total and anti-active TGF-b (R&D Systems), proliferating cell nuclear antigen (PCNA) as a measure of cell proliferation, and anti-Factor VIII-related antigen to determine MVD as a measure of angiogenesis (Dako, Carpinteria, CA). Slides with omission of the primary antibody served as the negative control. Cell types were identified by morphology. TGF-b staining intensity was graded by assigning a grade of 1, 2 or 3 to individual glands with staining positivity as o35%, 36-75% and 475% epithelial cells positive, respectively, and a score assigned by averaging gland intensity. A minimum of 25 glands per mouse were counted. PCNA and MVD were quantified as described. 5, 6 TSP-1 staining was quantified as previously described. 5 
Statistical Analysis
Statistical significance of the data was determined using Student's t-tests with P-values r0.05 considered significant.
RESULTS

DHT Increases Angiogenic Activity in Both Normal Prostate Epithelial and PCa Cells
We have observed that TSP-1 localizes to both the stromal and epithelial cells in human prostate tissue and that this TSP-1 expression is decreased in human PCa patient tissues. 5 We have also shown that normal PrECs secrete TSP-1 in vitro whereas the androgen-sensitive LNCaP and androgeninsensitive PC-3 PCa cell lines do not. 5 After castration, the drop in androgens initiates vascular regression that in turn induces tissue hypoxia. Therefore, we investigated the effects of both androgen and hypoxia on angiogenic activity and TSP-1 expression. We treated cells with DHT, a potent testosterone derivative, or incubated them in hypoxic conditions and tested angiogenic activity in the serum-free conditioned media using a microvascular endothelial cell migration assay. VEGF and TSP-1 levels were measured by ELISA and western blot analysis, respectively. In control experiments, DHT alone did not affect the migration of endothelial cells, indicating that DHT does not directly elicit angiogenesis (Supplementary Figure 1b) . However, DHT treatment did significantly increase angiogenic activity in PrECs at both the 10 À12 and 10 À10 M DHT doses, low and high proliferative doses, respectively, by more than 20% over untreated cells (Figure 1a ; Po0.05). With the 10 À7 M DHT treatment, a growth static dose, there was no change in angiogenic activity compared to untreated cells ( Figure 1a) . Similar results were obtained with androgen-sensitive LNCaP PCa cells. DHT treatment increased angiogenic activity by 16 and 25% at the 10 À12 and 10 À10 M doses, respectively, and again with no change at the 10 À7 M treatment, compared to untreated cells (Figure 1b ; Po0.05). Consistent with published studies, 7, 8, [11] [12] [13] 18 with the 10 À10 and 10 À7 M DHT treatments, VEGF levels were increased in both normal PrECs by 40 and 82%, respectively, and in LNCaP cells, by 47 and 29%, respectively (Figure 1c and d; Po0.05). TSP-1 secretion was not significantly altered by DHT treatment in PrECs (Figure 1e ). In our previous studies, the angiogenesis inhibitor PEDF was also not altered by DHT treatment. 6 Thus, in normal PrECs and androgen-sensitive PCa cells, androgens stimulate angiogenic activity due to increased VEGF levels.
Unlike Normal PrECs, Hypoxia Increases Angiogenic Activity in PCa Cells
In most cancer cells, hypoxia increases VEGF and angiogenic activity. In LNCaP cells, hypoxia stimulated angiogenic activity by almost 50% (Figure 2a ; Po0.05), and this increase in activity corresponded to a sixfold increase in VEGF (Figure 2b ; Po0.05). Because LNCaP cells do not secrete either TSP-1 or PEDF, 5, 6 the high level of VEGF may be responsible for the angiogenic induction. Similar results were obtained with the TSP-1 in prostate growth PP Fitchev et al androgen-insensitive PC-3 PCa cell line whereby hypoxia increased angiogenic activity by almost 50% and was associated with a threefold increase in VEGF (Figure 2a and b; Po0.05). Although PC-3 cells do not secrete TSP-1, 5 they do secrete PEDF, which we have previously reported to be downregulated by hypoxia; 6 thus, net angiogenic activity can be augmented by only a modest increase in VEGF.
In striking contrast to the cancer cells, hypoxia suppressed angiogenic activity secreted by normal PrECs by 45% compared to untreated (Figure 2c ; Po0.05). Although VEGF levels were increased by 41% with hypoxia compared to untreated cells, TSP-1 was inhibited by hypoxia or CoCl 2 , a chemical mimetic of hypoxia, by more than 30% (Figure 2d and e). Because we previously observed hypoxic induction of PEDF in these cells, 6 it appears that the PEDF is key to maintaining the antiangiogenic activity in normal epithelial cells under hypoxic stimuli.
Stromal Cell Response to DHT and Hypoxia Opposes That of Normal Epithelial Cells
As TSP-1 localizes to the prostate stroma in vivo and normal PrSCs secrete TSP-1 in vitro, 5 we tested the response of PrSCs to DHT and hypoxia as above. Surprisingly, in contrast to normal epithelial cells, angiogenesis was significantly decreased in PrSCs with DHT treatment by over 55% at all doses tested (10 À12 to 10 À7 M) compared to untreated cells (Figure 3a ; Po0.05). However, VEGF was increased threefold at 10 À12 M DHT, though higher concentrations had no effect compared to untreated cells (Figure 3b ; Po0.05). TSP-1 secretion was decreased in a dose-dependent manner by DHT treatment by 25-34% (Figure 3c ). Our previous experiments showed that DHT treatment also decreases PEDF in a dosedependent manner. 6 Thus, at the 10 À12 M DHT concentration, the TSP-1 and PEDF levels are likely still sufficient to inhibit angiogenesis even with the increased VEGF. The inhibition at the higher doses with decreased TSP-1 and PEDF suggests that additional molecules are involved.
In contrast to DHT treatment, hypoxia significantly increased angiogenic activity by 41% in PrSCs (Figure 3d ; Po0.05). Consistent with published studies, 33 hypoxia treatment increased PrSC VEGF secretion by 77% compared to untreated cells (Figure 3e ; Po0.05). However, TSP-1 secretion levels were not altered (Figure 3f ). Our previous experiments showed suppression of PEDF by hypoxia in these cells, 6 so this taken with the increase in VEGF may explain the net increase in angiogenic activity.
TSP-1 Contribution to Angiogenic Activity in Stromal Cells
To verify that the TSP-1 secreted by PrSCs under DHT or hypoxia treatment had antiangiogenic function, we tested activity in the presence of neutralizing TSP-1 antibody. Consistent with our previous results, 5 neutralizing TSP-1 antibody significantly increased secreted angiogenic activity (Figure 3g ; Po0.05). In this assay, we used CoCl 2 (100 mM) to mimic hypoxia, and in control experiments, CoCl 2 alone showed no affect on angiogenic activity (Supplementary Figure 1c) . In normal stromal cells, CoCl 2 treatment stimulated angio-inductive activity by 40% compared to untreated cells (Figure 3g ; Po0.05). Addition of neutralizing TSP-1 antibody further increased this activity by 42 and 98% compared to CoCl 2 -treated and CoCl 2 -untreated cells, respectively (Figure 3g ; Po0.05). Conversely, DHT treatment (10 À7 M) inhibited activity by 28%, but addition of neutralizing TSP-1 antibody relieved this inhibition, increasing activity by 90 and 36% compared to DHT-treated and DHT-untreated cells, respectively (Figure 3g ; Po0.05). When PrSCs were subjected to both DHT and CoCl 2 treatment, the net response was angio-inductive but was not significantly different from CoCl 2 alone (Figure 3g ). These data confirm that stromal-derived TSP-1 retains potent antiangiogenic activity and show that in the setting of androgen withdrawal-induced hypoxia, isolated stromal and epithelial cells have opposing angiogenic activity.
Epithelial Secretions Stimulate Stromal Angiogenic Response
As the blood vessels reside within the prostate stroma, it is likely that epithelial cell secretions modify the stromal angiogenic response. To investigate this, we incubated PrSCs in media conditioned by PrECs grown under normal or hypoxic conditions. Because PrSCs are grown in a different culture media than PrECs, we tested the effects of the PrEC media alone on PrSCs as a control, and we did observe an increase in angiogenic activity of PrSCs (Po0.05; Figure 4a ). However, incubation of PrSCs in media conditioned by PrECs significantly increased activity by 25% over that of the epithelial media alone (Po0.03; Figure 4a ). Moreover, incubation of PrSCs in media conditioned by PrECs grown in hypoxic conditions further increased activity by an additional 35% (Po0.003; Figure 4a ). Consistent with the results above, hypoxia increased VEGF levels in PrECs (Figure 4b ). Although incubation of PrSCs in epithelial media alone did not alter VEGF levels, incubation in media conditioned by PrECs from both normoxic and hypoxic conditions significantly increased VEGF levels by twofold compared to the media control (Po0.005; Figure 4b ). However, VEGF levels were not different between PrSCs treated with PrEC normoxia or hypoxia conditioned media (Figure 4b) . The increase in angiogenic activity was independent of TSP-1 or PEDF because their expression levels were not changed (Figure 4c ). These data show that epithelial signals can stimulate stromal angiogenic activity primarily through changes in VEGF expression. 
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TSP-1 Expression Increases in Response to Androgen Ablation in Vivo
Because DHT and hypoxia modify PrEC and PrSC angiogenic activity and TSP-1 expression in vitro in opposing directions, we asked if androgens suppressed TSP-1 expression in vivo using a mouse castration model and human PCa tissues. We observed localization of TSP-1 in both the stromal and epithelial compartments of the ventral, lateral and dorsal lobes of the intact mouse prostate (Figure 5a ). Although epithelial expression was variable between glands, it was upregulated in the dorsal prostate lobe by 3 days after castration (Figure 5a ).
These observations are consistent with a study in rats showing an increase in TSP-1 expression in post-castration tissues. 21 We graded the TSP-1 staining in the epithelium and stroma, showing a significant increase in staining in both compartments after castration (Figure 5b ; n ¼ 5 per group; Po0.008). As expected, MVD was reduced in the castrated tissues (3.4 ± 0.43 vs 1.92 ± 0.39; Po0.003). To determine if MVD correlated with TSP-1 staining, we calculated an MVD/ TSP-1 staining ratio, and this ratio was significantly decreased in the castrated mice (Figure 5c ; Po0.012). We have previously shown that in human PCa specimens there is a Significantly increased compared to untreated or DHT treated, Po0.002, but not significantly different than CoCl 2 alone, P ¼ 0.64. p Significantly increased over the combined hypoxia and DHT treatment sample, Po0.00001.
positive correlation between MVD/TSP-1 ratio and higher grade cancers, 5 and other studies have shown that stromal MVD decreases after ADT in human cancer tissues. 34, 35 In addition, one study has reported that patients undergoing ADT have increased TSP-1 levels compared to patients who had not undergone ADT. 4 However, a direct correlation between androgen-withdrawal and TSP-1 expression was not possible in this study. Therefore, we addressed this question by examining TSP-1 expression in patient-matched PCa biopsy specimens taken before and 3-7 days after androgenablation therapy. In pre-therapy specimens, TSP-1 was minimal to absent in both the stromal and epithelial cell compartments (Figure 5d ). In two of eight cases, the posttherapy TSP-1 staining remained unchanged compared to the pre-therapy, with only focal epithelial staining present in these specimens. However, in the other six cases, there was a marked increase in TSP-1 staining in the epithelial cells with some focal stromal positivity noted after therapy (Figure 5d ). When quantified, the TSP-1 staining was significantly increased in the epithelial compartment (Po0.013) whereas the stromal staining was not increased (Figure 5e ). Taken together, these observations suggest that TSP-1 functions in the vascular regression induced by androgen withdrawal. As we have similar results with PEDF expression (increase in seven of eight of patient tissues 6 ), it seems that angiogenesis inhibitors have a critical role in mediating ADT-induced cancer regression.
Loss of TSP-1 Expression in the Mouse Results in Prostate Hyperplasia
We and others have previously reported that loss of TSP-1 disrupts the normal architecture of several tissues, including the lungs, pancreas, liver and testes; 23, 32 however, the prostate phenotype has not been reported. The prostate in TSP-1 KO was compared to age-matched C57Bl/6 wild-type mice, the background strain of the TSP-1 KO with a minimum of five mice per group analyzed. In the TSP-1 KO, we observed dysregulated epithelial growth in the ventral, dorsal and lateral lobes of the prostate, as compared to controls ( Figure 6 ). Hyperplasia was present in both the ventral TSP-1 in prostate growth PP Fitchev et al and dorsal lobes and was evident by 3 months of age and progressive with age. The hyperplasia was characterized by increased tufting, stratification of cells in the epithelial cell layer with non-basally located, hyperchromatic and pleomorphic nuclei. In the lateral prostate, there was also a metaplasia phenotype evident by regions of cells with mucin accumulation, which does not normally occur in the lateral prostate. The epithelial hyperplasia was characterized by immunostaining prostate tissues with antibody against PCNA and factor VIII-related antigen for proliferation and MVD, respectively (Figure 7a and b; n ¼ 6 per group). TSP-1 KO mice showed a twofold increase in percent PCNA-positive epithelial nuclei when compared to wild-type mice (Po0.007; Figure 7c ), and stromal MVD was increased twofold in the TSP-1 KO prostate tissues as compared to wild-type controls (Po0.0003; Figure 7d ). These data show that TSP-1 function is necessary for in vivo regulation of prostate growth, and the increase in stromal MVD supports angiogenic regulation as one mechanism of this growth regulation.
TSP-1 Activates TGF-b in the Mouse Prostate TSP-1 is a multifunctional protein, and in addition to its antiangiogenic activity, TSP-1 can also activate latent TGF-b in vivo in other tissue types, 23 but prostate activation has not been investigated. As TGF-b is a key regulator of prostate growth, we examined prostate tissues from wild-type and TSP-1 KO mice by immunostaining, using antibodies against total and active TGF-b. With the antibody against total TGF-b, there was no difference in immunoreactivity between wild-type and TSP-1 KO tissues (Figure 8a and b; n ¼ 5 per group). With antibody against active TGF-b, staining was similar between wild-type and TSP-1 KO in the lateral and ventral lobes of the prostate. However, in the TSP-1 KO dorsal prostate, there was significantly less active TGF-b compared to wild-type tissues (Figure 8c and d) . (d) Patient-matched biopsies were taken from PCa patients before and 3-7 days after androgen ablation therapy. Six of eight patient tissues showed increased immunoreactivity after androgen ablation therapy. Pre-and post-therapy tissues are shown for two patients. (e) TSP-1 staining was graded on a 1-4 scale in the epithelial and stromal compartments. *Significantly increased in castrated compared to intact, Po0.012, and **significantly increased in human post-ADT tissues, Po00.013.
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When this staining was quantified by grading staining intensity within the glands on a 1-3 scale, there was significantly fewer high-staining glands (grade 3) in the TSP-1 KO prostate as compared to the wild-type tissues (Po0.001; Figure 8e ). These data identify a novel function for TSP-1 in the prostate and suggest that TSP-1 activation of TGF-b is lobe specific. This difference may have significance as the dorsal lobe is considered to be the most analogous to the human prostate peripheral zone where the majority of PCa arises. Figure 6 The TSP-1 KO mouse has prostate hyperplasia. Compared to wild-type (WT) mouse, the TSP-1 KO (TSP KO) mouse prostate showed epithelial and stromal cell hyperplasia by 3 months of age with nuclear atypia (hyperchromatic and pleomorphic nuclei) in the glandular cells. Evidence of hyperplasia was observed in the ventral prostate (VP), dorsal prostate (DP) and lateral prostate (LP). Representative H&E sections are shown at 5-6 months of age.
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From studies in other tissue types, it also appears that active TGF-b can induce TSP-1 expression, showing a positive feedback regulation. To investigate this in prostate cells, we treated PrSCs with neutralizing TGF-b antibodies. TSP-1 secretion in treated cells was suppressed 25% compared to untreated cells (Figure 8f ). In addition, above we show that treatment with 10 À7 M DHT did not induce VEGF expression ( Figure 3b) ; however, when neutralizing TGF-b antibody was added, VEGF was significantly increased (Figure 8g ). Although TGF-b can act directly on endothelial cells, these data suggest that in the prostate it also contributes to angiogenic regulation through inducing TSP-1 expression and suppressing VEGF expression.
To determine if TSP-1 activates TGF-b in vivo after androgen withdrawal, we castrated wild-type and TSP-1 KO mice, collected prostate tissues at 1-21 days after castration and immunostained for total and active TGF-b. In the castrated tissues, with antibody against total TGF-b, no differences were observed between wild-type and TSP-1 KO mice. In the wild-type mice, there was a characteristic thickening of the stroma by 3 days after castration compared to the intact animals, and active TGF-b strongly localized to this region (Figure 9a and b) . Although some of this staining is nonspecific staining of the red blood cells leaking from the regressing vasculature, stromal positivity is also evident (Figure 9b ). In contrast, TSP-1 KO mice did not show a thickening of the stroma and active TGF-b levels were unchanged in post-castration tissues (Figure 9c and d) . These observations suggest that TSP-1 expression is necessary for the stromal response by increasing TGF-b activation in postcastration tissues.
DISCUSSION
The importance of angiogenesis in tumor growth is well established, and a growing body of data supports its importance in regulating normal organ homeostasis as well. Prostate development and maintenance of the adult gland is dependent on androgens, and this appears to be mediated in part by regulation of angiogenesis. Androgen withdrawal induces regression of the glandular epithelium; however, endothelial apoptosis and vascular regression precedes the epithelial apoptosis. [18] [19] [20] While the role of the angiogenesis inducer, VEGF, is well studied in this process, the role of angiogenesis inhibitors has not been well established. Although the initial vascular regression can be explained by a sharp decrease in VEGF expression, 14 the vascular regression leads to tissue hypoxia and VEGF returns to baseline levels. [18] [19] [20] As the vascular regression continues, other angiogenic mediators must be involved. Here we show that TSP-1 expression increases after androgen withdrawal in normal mouse prostate tissues and in human PCa tissues. Thus, the antiangiogenic activity of TSP-1 would contribute to the continued vascular regression. Similarly, we have observed upregulation of PEDF in response to androgen withdrawal in normal mouse prostate and human PCa tissues. 6 These observations suggest that angiogenesis inhibitors are critical to androgen-mediated regulation of the stromal vasculature. These data are of particular interest because ADT is a primary therapy for metastatic disease and is used in conjunction with other therapies in locally advanced PCa. Supporting this, ADT has been shown to decrease stromal MVD in human PCa tissues. 34, 35 The reexpression of TSP-1 shown above, and our previous study showing reexpression of PEDF, 6 both most strongly in the epithelial cells, suggests a critical role for these angiogenesis inhibitors in mediating ADT-induced PCa regression and that analysis of their expression after ADT could provide prognostic information.
As the prostate endothelial cells do not express the androgen receptor, 15, 16 it is likely that the epithelial and stromal cells mediate this response. To dissect this, we tested the androgen-and hypoxia-mediated angiogenic response in both cell types. Surprisingly, they revealed opposing responses in vitro. In epithelial cells, TSP-1 expression was suppressed by hypoxia, whereas in stromal cells hypoxia had no effect. With DHT treatment, however, stromal TSP-1 was suppressed whereas epithelial cell TSP-1 was not affected. Though other molecules likely contribute, the net angiogenic activity in response to either stimulus could be explained when VEGF, TSP-1 and PEDF levels were considered. With these opposing responses, it seemed likely that the in vivo response may be modified by cell interactions. Toward this, we showed that stromal cell angiogenic activity is stimulated by epithelial cell secretions and that this modulation was sensitive to changes in epithelial growth in normoxia vs hypoxia. Although these data show a complex regulation of angiogenic mediators by stromal-epithelial interactions, they also show two caveats in angiogenic research. The first is that testing isolated epithelial cancer cells may not be representative of in vivo angiogenic activity, and the second is that measuring a single angiogenic mediator may not be an accurate indicator of angiogenic balance in the tissue.
Further supporting the critical role of angiogenesis and the inhibitor TSP-1 in regulating prostate growth, we also show that developmental loss of TSP-1 leads to prostate epithelial hyperplasia in mice, characterized by both increased epithelial cell proliferation and increased stromal angiogenesis. This phenotype was similar to the phenotype we observed in PEDF KO mice. Both molecules regulate prostate growth TSP-1 in prostate growth PP Fitchev et al through vascular inhibition, and PEDF can also induce apoptosis of PCa cell. 6 We have previously shown that TSP-1 and PEDF expression are decreased in PCa tissues compared to benign tissues. 5, 6 And, others have shown that circulating TSP-1 levels are decreased in PCa serum as compared to patients with benign prostatic hyperplasia and that these levels differentiated benign vs malignant disease. 36 These observations suggest a broader function of angiogenic inhibitors as growth regulators in the prostate.
TSP-1 and TSP-1-derived peptides have also shown efficacy in directly inhibiting PCa cell proliferation in vitro 37 and xenograft growth in vivo. 38, 39 However, one study has noted that, in a LNCaP xenograft model, the tumors eventually escaped the inhibitory effects of TSP-1, 21 which could be linked to progression to hormone-independent cancer. In this study, we show that TSP-1 activated latent TGF-b in the mouse prostate. TGF-b is a negative regulator of normal PrECs. In human PCa, early stage cancers are sensitive to the growth inhibitory effects of TGF-b; however, advanced stage cancers are insensitive due to mutated or decreased expression of TGF-b receptors and altered intracellular signaling pathways. Thus, decreased sensitivity to the growth inhibitory effects of TGF-b may be one mechanism by which tumors become insensitive to TSP-1 inhibition. Therefore, if TSP-1 expression is lost during tumorigenesis, multiple blockades to tumor growth are lost, including inhibition of stromal angiogenesis and activation of latent TGF-b. Thus, for PCa patients, combining ADT with an antiangiogenic therapy, such as a VEGF-neutralizing therapy or a TSP-1 therapy, and/or a therapy targeting the TGF-b pathway, could delay time to recurrence to androgen-independent disease.
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